Merck Frosst Canada, Inc.

Merck + Co., Inc.

Merck Frosst Canada & Co.

Merck Canada Inc.

Renata Oballa

Joel S Robichaud

Cameron Black

Sheldon N Crane

Rejean Fortin

Chun Sing Li

Eduardo Setti

Christopher I Bayly

Rohan V Mendonca

Yeeman K Ramtohul

Denis Deschenes

Daniel J McKay

Shankar Venkatraman

Elise Isabel

Dan-Xiong Wang

Daniel J Mckay

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; fatty liver disease and cancer. 

Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase

This invention relates to a class of compounds having the general formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Compounds and compositions as protease inhibitors

Growing community of inventors

Kirkland, Canada

Renata Oballa